Overview Dividends

(GLPG) Galapagos - Ratings and Ratios

Exchange: NASDAQ • Country: Belgium • Currency: USD • Type: Common Stock • ISIN: US36315X1019

Medicine, Oncology, Immunology, CAR-T, Biotech

GLPG EPS (Earnings per Share)

EPS Growth (3Y CAGR): 314.42%
EPS Trend (3Y Correlation): -20.7%

GLPG Revenue

Revenue Growth (3Y CAGR): -10.01%
Revenue Trend (3Y Correlation): 9.1%

Risk via 10d forecast
Volatility	29.8%
Value at Risk 5%th	43.8%
Relative Tail Risk	-10.65%

Reward TTM
Sharpe Ratio	0.42
Alpha	6.35

Character TTM
Hurst Exponent	0.366
Beta	0.408
Beta Downside	0.327

Drawdowns 3y
Max DD	52.73%
Mean DD	30.22%
Median DD	31.93%

Description: GLPG Galapagos November 10, 2025

Galapagos NV (NASDAQ:GLPG) is a Belgium-based biotech focused on developing small-molecule and cell-therapy candidates for oncology and immunology, primarily targeting the U.S. and European markets.

Its current pipeline includes four point-of-care CAR-T programs: GLPG5101 (CD19 CAR-T for relapsed/refractory non-Hodgkin lymphoma), GLPG5201 (CD19 CAR-T for relapsed/refractory chronic lymphocytic leukemia), GLPG5301 (BCMA CAR-T for relapsed/refractory multiple myeloma), and GLPG3667, which has completed a Phase 1b trial. All CAR-T candidates are in Phase 1/2, indicating early-stage clinical risk but also the potential for rapid value creation if efficacy and safety benchmarks are met.

Strategic collaborations with Gilead Sciences and AbbVie provide non-dilutive funding and development expertise; to date, Galapagos has received over €300 million in upfront and milestone payments, which helps offset its cash burn of roughly €150 million per year (FY 2024). The company’s market capitalization is approximately $7 billion, giving a price-to-cash-burn multiple of about 4.5×, modest relative to the broader CAR-T sector where peers trade at 6–10×.

Key sector drivers that could amplify Galapagos’ upside include the projected CAGR of ~15 % for the global CAR-T market through 2030 and increasing reimbursement willingness for point-of-care manufacturing, which reduces logistics costs and expands access in community hospitals.

For a deeper quantitative assessment, you may want to explore ValueRay’s detailed valuation models for GLPG.

GLPG Stock Overview

Market Cap in USD	2,161m
Sub-Industry	Biotechnology
IPO / Inception	2005-05-06
Return 12m vs S&P 500	0.22%
Analyst Rating	2.50 of 5

GLPG Dividends

Currently no dividends paid

GLPG Growth Ratios

CAGR 3y	-8.69%
CAGR/Max DD Calmar Ratio	-0.16
CAGR/Mean DD Pain Ratio	-0.29
Current Volume	173.9k
Average Volume	173.9k

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-436.0m TTM) > 0 and > 6% of Revenue (6% = 17.2m TTM)

FCFTA -0.07 (>2.0%) and ΔFCFTA 2.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 1145 % (prev 1338 %; Δ -193.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.07 (>3.0%) and CFO -269.4m > Net Income -436.0m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 8.63 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (65.9m) change vs 12m ago -0.08% (target <= -2.0% for YES)

Gross Margin -38.90% (prev 56.80%; Δ -95.71pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 6.91% (prev 5.75%; Δ 1.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -10.69 (EBITDA TTM -503.2m / Interest Expense TTM 24.4m) >= 6 (WARN >= 3)

Altman Z'' 3.98

(A) 0.80 = (Total Current Assets 3.72b - Total Current Liabilities 430.7m) / Total Assets 4.13b

(B) -0.16 = Retained Earnings (Balance) -678.8m / Total Assets 4.13b

(D) -0.27 = Book Value of Equity -340.8m / Total Liabilities 1.25b

Total Rating: 3.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 40.14

1. Piotroski 0.50pt = -4.50

2. FCF Yield 16.75% = 5.0

3. FCF Margin data missing

4. Debt/Equity 0.00 = 2.50

5. Debt/Ebitda 0.13 = 2.49

6. ROIC - WACC (= -16.43)% = -12.50

7. RoE -15.62% = -2.50

8. Rev. Trend 9.13% = 0.68

9. EPS Trend -20.71% = -1.04

What is the price of GLPG shares?

As of November 17, 2025, the stock is trading at USD 31.29 with a total of 173,924 shares traded.
Over the past week, the price has changed by -3.57%, over one month by -8.21%, over three months by -4.92% and over the past year by +15.89%.

Is Galapagos a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Galapagos (NASDAQ:GLPG) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 40.14 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GLPG is around 27.20 USD . This means that GLPG is currently overvalued and has a potential downside of -13.07%.

Is GLPG a buy, sell or hold?

Galapagos has received a consensus analysts rating of 2.50. Therefor, it is recommend to sell GLPG.

Strong Buy: 0
Buy: 0
Hold: 4
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the GLPG price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	27.6	-11.9%
Analysts Target Price	27.6	-11.9%
ValueRay Target Price	30.1	-4%

GLPG Fundamental Data Overview November 15, 2025

Market Cap EUR = 1.86b (2.16b USD * 0.8615 USD.EUR)
P/E Forward = 344.8276
P/S = 7.5308
P/B = 0.7529
Beta = -0.05
Revenue TTM = 286.9m EUR
EBIT TTM = -260.7m EUR
EBITDA TTM = -503.2m EUR
Long Term Debt = 7.50m EUR (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.04m EUR (from shortTermDebt, last quarter)
Debt = 8.81m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -66.9m EUR (from netDebt column, last quarter)
Enterprise Value = -1.71b EUR (1.86b + Debt 8.81m - CCE 3.58b)
Interest Coverage Ratio = -10.69 (Ebit TTM -260.7m / Interest Expense TTM 24.4m)
FCF Yield = 16.75% (FCF TTM -287.0m / Enterprise Value -1.71b)
FCF Margin = -100.0% (FCF TTM -287.0m / Revenue TTM 286.9m)
Net Margin = -151.9% (Net Income TTM -436.0m / Revenue TTM 286.9m)
Gross Margin = -38.90% ((Revenue TTM 286.9m - Cost of Revenue TTM 398.5m) / Revenue TTM)
Gross Margin QoQ = -275.5% (prev 92.79%)
Tobins Q-Ratio = -0.42 (set to none) (Enterprise Value -1.71b / Total Assets 4.13b)
Interest Expense / Debt = 266.8% (Interest Expense 23.5m / Debt 8.81m)
Taxrate = 7.90% (-17.5m / -221.5m)
NOPAT = -240.1m (EBIT -260.7m * (1 - 7.90%)) [loss with tax shield]
Current Ratio = 8.63 (Total Current Assets 3.72b / Total Current Liabilities 430.7m)
Debt / Equity = 0.00 (Debt 8.81m / totalStockholderEquity, last quarter 2.88b)
Debt / EBITDA = 0.13 (negative EBITDA) (Net Debt -66.9m / EBITDA -503.2m)
Debt / FCF = 0.23 (negative FCF - burning cash) (Net Debt -66.9m / FCF TTM -287.0m)
Total Stockholder Equity = 2.79b (last 4 quarters mean from totalStockholderEquity)
RoA = -10.56% (Net Income -436.0m / Total Assets 4.13b)
RoE = -15.62% (Net Income TTM -436.0m / Total Stockholder Equity 2.79b)
RoCE = -9.32% (EBIT -260.7m / Capital Employed (Equity 2.79b + L.T.Debt 7.50m))
RoIC = -8.95% (negative operating profit) (NOPAT -240.1m / Invested Capital 2.68b)
WACC = 7.48% (E(1.86b)/V(1.87b) * Re(7.52%) + (debt cost/tax rate unavailable))
Discount Rate = 7.52% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.09%
Fair Price DCF = unknown (Cash Flow -287.0m)
EPS Correlation: -20.71 | EPS CAGR: 314.4% | SUE: 0.16 | # QB: 0
Revenue Correlation: 9.13 | Revenue CAGR: -10.01% | SUE: 0.02 | # QB: 0

Additional Sources for GLPG Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle